Published in:
01-08-2018 | Correction
Correction to: Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology
Published in: Clinical and Translational Oncology | Issue 8/2018
Login to get accessExcerpt
On page 5 of the article, in the last paragraph of the section “Prognostic genetic platforms: molecular phenotypes and translation to the clinic” a relevant discrepancy between the text and Table 1 could be misunderstood, therefore the paragraph was corrected. The corrected version as well as some changes in Tables 1 and 2 that reflect the updated modifications are shown here:
Table 1
Usage recommendations for different genetic tests as prognostic tools or to establish the benefit of adding chemotherapy to hormone therapy in the management of breast cancer
|
Oncotype DX®
|
MammaPrint®
|
Prosigna® (PAM50)
|
EndoPredict®
|
|
|---|---|---|---|---|
|
ASCO 2017 [1]
|
Guides the decision to prescribe adjuvant systemic chemotherapy
Evidence: high
Recommendation: strong
|
May be used in ER/PR positive, HER2 negative, high risk breast cancer
Node-negative
Evidence: high
Recommendation: strong
Node-positive (1–3 nodes)a
Evidence: high
Recommendation: moderate
It should not be used in either ER/PR positive low risk per MINDACT, HER2 positive or triple negative breast cancer
|
Guides the decision to prescribe adjuvant systemic chemotherapy together with other clinical and pathological variables
Evidence: high
Recommendation: strong
|
Guides the decision to prescribe adjuvant systemic chemotherapy
Evidence: intermediate
Recommendation: moderate
|
|
NCCN 2017 [2]
|
The only test recommended for patients with > 0.5 cm tumour
Oncotype DX®: can be considered for selecting patients with 1–3 ipsilateral lymph nodes involved
The only test validated for predicting chemotherapy response
|
Prognostic value, but not validated for predicting chemotherapy response
|
||
|
St Gallen 2017 [3]
|
Prognostic value and predictive of the benefit of adjuvant chemotherapy in node-negative tumors. No role in clinical low risk patients, where chemotherapy would not be indicated
|
|||
|
SEOM
|
5-year recurrence risk prognosis: IA/IB
10-year recurrence risk prognosis: IB
Chemotherapy benefit prediction: IA/IB
|
5-year recurrence risk prognosis: IB
10-year recurrence risk prognosis: –
Chemotherapy benefit prediction: –
|
5-year recurrence risk prognosis: IB
10-year recurrence risk prognosis: IB
Chemotherapy benefit prediction: –
|
5-year recurrence risk prognosis: IB
10-year recurrence risk prognosis: IB
Chemotherapy benefit prediction: –
|
|
IMPAKT
|
Little but significant prognostic information above and beyond clinical and pathological parameters. No evidence of clinical usefulness for modifying the treatment decision.
|
|||
Table 2
Prognostic and predictive value of different genetic tests in breast cancer
|
ASCO 2017 [1]
|
NCCN 2017 [2]
|
St Gallen 2017 [3]
|
SEOM 2015
|
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prognosis
|
CT benefit prediction
|
Prognosis
|
CT benefit prediction
|
Prognosis
|
CT benefit prediction
|
Prognosis
|
CT benefit prediction
|
||||
|
5 years
|
10 years
|
5 years
|
10 years
|
5 years
|
10 years
|
||||||
|
Oncotype DX®
|
Yes
|
NA
|
Yes
|
Yes
|
Yes
|
+++
|
+++
|
Yes
|
IA (low RS)
IB (other RSs)
|
IB
|
IA (low RS)
IB (other RSs)
|
|
Prosigna®
|
Yes
|
Yes
|
Yes
|
Yes
|
NA
|
++
|
++
|
Yes
|
IB
|
IB
|
NA
|
|
MammaPrint®
|
Yes
|
No
|
Yes
|
Yes
|
NA
|
+++
|
NA
|
Yes
|
IB
|
NA
|
NA
|
|
EndoPredict®
|
Yes
|
Yes
|
Yes
|
Yes
|
NA
|
++
|
++
|
Yes
|
IB
|
IB
|
NA
|